Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone pr

Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone pr

Item
http://www.wikidata.org/entity/Q33420122
Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and CanadaEquivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler.Establishing bioequivalence for inhaled drugs; weighing the evidence.Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.Scientific Rationale for Determining the Bioequivalence of Inhaled Drugs.Product lifecycle approach to cascade impaction measurements.A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.Tailoring of corticosteroids in COPD management.Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone propionate and salmeterol.Considerations in establishing bioequivalence of inhaled compounds.Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.Pharmacokinetic study for the establishment of bioequivalence of two inhalation treatments containing budesonide plus formoterol.Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood.LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
P2860

Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone pr

Item
http://www.wikidata.org/entity/Q33420122
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacokinetic, pharmacodynam ...... l 50 microg and fluticasone pr
@ast
Pharmacokinetic, pharmacodynam ...... l 50 microg and fluticasone pr
@en
type
label
Pharmacokinetic, pharmacodynam ...... l 50 microg and fluticasone pr
@ast
Pharmacokinetic, pharmacodynam ...... l 50 microg and fluticasone pr
@en
prefLabel
Pharmacokinetic, pharmacodynam ...... l 50 microg and fluticasone pr
@ast
Pharmacokinetic, pharmacodynam ...... l 50 microg and fluticasone pr
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Pharmacokinetic, pharmacodynam ...... l 50 microg and fluticasone pr
@en
P2093
P304
P31
P356
10.1016/J.CLINTHERA.2009.02.007
P433
P478
P577
P698
P921